4th Serosurvey of Tamil Nadu: Infection and Vaccine Generated Hybrid Immunity



Abstract Views
332

Downloads
284

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Sep 28, 2022
Published Mar 14, 2023
10.24018/ejmed.2023.5.2.1525

Abstract viewed = 332 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Salient findings of the fourth serological survey of SARS-CoV-2 infections conducted among the age cohort above 10 years in Tamil Nadu (India) have been described. The overall seroprevalence of 87% was reported in the survey done in December 2021, whereas in the first, second, and third surveys, the seropositivity was 32%, 29%, and 70%, respectively. The % share of the antibodies formed due to vaccination in the third and fourth surveys have the contributions of 6.2% and 28.3%, respectively as per the vaccination record of the state since the above given proportion of the state’s population (full population) was fully vaccinated (two-dose) by the time the two surveys were conducted. Age-wise break up of seropositivity of the fourth survey showed that the cohort of 10-18 years had the least (68.4%) seroprevalence and adults above 60 had the highest at 84.5%. The rate of the spread of the virus decreased due to the hybrid immunity developed by infection and vaccination. Using the vaccination and serological data, the % enhancement of the antibodies formed due to vaccination has been worked out in the real world on the ground.

Keywords: Delta variant hybrid immunity SARS-CoV-2 mutation serosurvey in Tamil Nadu vaccine generated immunity

Downloads

Download data is not yet available.

References

  1. COVID-19 Cases in Japan and Worldwide (Real-Time Updates) [Internet] 2023 Available from: https://www.nippon.com/en/japan-data/h00901/
     Google Scholar
  2. Coronavirus (COVID-19)-Google News (Japan) [Internet] Available from: https://news.google.com/covid19/map?hl=en-US&gl=US&ceid=US%3Aen&mid=%2Fm%2F03_3d
     Google Scholar
  3. The Japan Times. Japan COVID deaths up sevenfold over month amid latest virus wave. [Internet] 2022 Available from: https://www.japantimes.co.jp/news/2022/08/16/national/covid-deaths/
     Google Scholar
  4. The Japan Times. Vaccines and immunity through infection may be behind fall in seventh-wave cases. [Internet] 2022 Available from: https://www.japantimes.co.jp/news/2022/09/20/national/science-health/seventh-wave-downtrend/
     Google Scholar
  5. The Japan Times. Japan to start giving omicron-targeting booster shots Sept. 20. [Internet] 2022 Available from: https://www.japantimes.co.jp/news/2022/09/14/national/new-vaccine-rollout-start-date/
     Google Scholar
  6. The Japan Times. Japan looks to sewage to gain new insight into state of pandemic. [Internet] 2022 Available from: https://www.japantimes.co.jp/news/2022/08/21/national/science-health/coronavirus-wastewater-monitoring-projects/
     Google Scholar
  7. Outlook India. Antibodies That May Lead to Next-gen Vaccines For All Covid Strains Found. [Internet] 2022 Available from: https://www.outlookindia.com/national/antibodies-that-may-lead-to-next-gen-vaccines-for-all-covid-strains-found-news-215875
     Google Scholar
  8. COVID-19: Antibodies to lead to next-gen vaccines effective against all Covid strains found. Mint. [Internet] 2022 [cited 2022 August 12] Available from: https://www.livemint.com/news/world/covid19-antibodies-effective-against-next-gen-vaccines-for-all-covid-strains-found-details-here-11660315055611.html
     Google Scholar
  9. Shervani Z, Qazi UY, Khan MJ, Fatma K, Siddiquie A, Vuyyuru VP, et al. COVID-19 in Karnataka: Rise of Omicron. European Journal of Medical and Health Sciences. 2022; 4(6): 71-76.
    DOI  |   Google Scholar
  10. Shervani Z, Jamal N, Qazi UY, Hasan S, Fatma K, Siddiquie A, et al. Prevalence and Pathogenicity of Omicron Varian. European Journal of Medical and Health Sciences. 2022; 4(5): 125-32.
    DOI  |   Google Scholar
  11. Shervani Z, Bhardwaj D, Sherwani A, Khan I, Qazi UY. COVID-19 infection in 8 big cities of India: The Dynamics of the Spread and Seropositivity. European Journal of Medical and Health Sciences. 2021; 3(6): 1-5.
    DOI  |   Google Scholar
  12. Shervani Z, Bhardwaj D, Nikhat R. COVID-19 infection in India: Seropositivity versus the Dynamics of the Spread. European Journal of Medical and Health Sciences. 2021; 3(4): 95-99.
    DOI  |   Google Scholar
  13. Shervani Z, Bhardwaj D, Nikhat R. Ibbrahim A, Hasan S, Khan I, et al. Serosurvey of Haryana and Odisha: COVID-19 Hybrid Immunity. European Journal of Medical and Health Sciences. 2022; 4(2): 27-32.
    DOI  |   Google Scholar
  14. Shervani Z, Bhardwaj D, Nikhat R. Ibbrahim A, Khan I, Qazi UY, et al. 4th National Sero Survey of India: Vaccine Generated Antibodies Enhancement. European Journal of Medical and Health Sciences. 2022; 4(1): 27-32.
    DOI  |   Google Scholar
  15. Shervani Z, Bhardwaj D, Nikhat R. Ibbrahim A, Khan I, Hasan S, et al. 5th and 6th Sero Survey of Delhi: Vaccine Activated Antibodies Enhancement. European Journal of Medical and Health Sciences. 2022; 4(1): 61-66.
    DOI  |   Google Scholar
  16. Shervani Z. COVID-19 in Kerala: Health Index Theory. European Journal of Medical and Health Sciences. 2021; 3(2): 21-24.
    DOI  |   Google Scholar
  17. Shervani Z. COVID-19 in Kerala: The Dynamics of Spread and Health Index Theory. RAS Medical Science. 2021; 1(2): 1-3.
    DOI  |   Google Scholar
  18. Shervani Z, Bhardwaj D, Nikhat R. Dharavi Slums (Mumbai, India): The Petri Dish of COVID-19 Herd Immunity. European Journal of Medical and Health Sciences. 2021; 3(3): 38-41.
    DOI  |   Google Scholar
  19. Shervani Z, Khan I, Siddiqui NY, Khan T, Qazi UY. Viability of SARS-CoV-2 and Sanitization Methods. European Journal of Medical and Health Sciences. 2021; 3(1): 22-27.
    DOI  |   Google Scholar
  20. Shervani Z, Khan I, Qazi UY. COVID-19 vaccine. Advances in Infectious Diseases. 2020; 10(3): 195-210.
    DOI  |   Google Scholar
  21. Shervani Z, Khan I, Khan T, Qazi UY. World’s fastest supercomputer picks COVID-19 drug. Advances in Infectious Diseases. 2020; 10(3): 211-225.
    DOI  |   Google Scholar
  22. Shervani Z, Fatma K, Hasan S, Siddiquie A, Vuyyuru VP, Jamal N, et al.Mild Nature of SARS-CoV-2 Breakthrough Infections in Healthcare Workers in India. European Journal of Medical and Health Sciences. 2022; 4(4): 26-33.
    DOI  |   Google Scholar
  23. Shervani Z, Nikhat R, Hasan S, Qazi UY, Fatma K, Siddiquie A, et al. COVID-19 in India: Breakthrough Infections in Delta Wave. European Journal of Medical and Health Sciences. 2022; 4(4): 12-16.
    DOI  |   Google Scholar
  24. Shervani Z, Bhardwaj D, Purang M, Ibbrahim A, Vuyyuru VP, Hasan S, et al.The Omicron Variant: Prevalence, Transmissibility, and Pathogenicity. European Journal of Medical and Health Sciences. 2022; 4(3): 84-91.
    DOI  |   Google Scholar
  25. Shervani Z, Bhardwaj D, Hasan S, Qazi UY, Purang M, Ibbrahim A, et al. The Omicron Wave in India, Mumbai, and Delhi: Prevalence and Pathogenicity. European Journal of Medical and Health Sciences. 2022; 4(3): 123-130.
    DOI  |   Google Scholar
  26. The Hindu. 87% of T.N. has antibodies against SARS-CoV-2, reveals fourth sero-survey. [Internet] 2022 Available from: https://timesofindia.indiatimes.com/city/chennai/87-of-people-in-tamil-nadu-have-antibodies-against-covid-survey/articleshow/89463991.cms
     Google Scholar
  27. covid19bharat.in [Internet] Available from: https://covid19.theavtar.com/
     Google Scholar
  28. The Hindustan Times. 20-30% people lose natural immunity against Covid in 6 months, new study finds. April 11, 2021. [Internet] 2022 Available from: https://www.businesstoday.in/latest/trends/story/20-30-recovered-people-lose-natural-immunity-against-covid-19-in-6-months-293192-2021-04-11
     Google Scholar


Most read articles by the same author(s)

1 2 > >>